Media release

Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany

Retrieved on: 
Friday, November 10, 2023
Investment, Penicillin, EUR, API, Media release, Fine chemical, Generic drug, Kundl, Novartis, Holzkirchen

The inauguration of a new facility for production of penicillin at Kundl, Austria, and a new biosimilar development center in Holzkirchen, Germany, reaffirm the dual Sandoz commitment to ensuring sustainable access to quality antibiotics and spearheading development of biosimilars.

Key Points: 
  • The inauguration of a new facility for production of penicillin at Kundl, Austria, and a new biosimilar development center in Holzkirchen, Germany, reaffirm the dual Sandoz commitment to ensuring sustainable access to quality antibiotics and spearheading development of biosimilars.
  • Sandoz has the only major remaining vertically-integrated production network for penicillins in Europe; penicillins are the leading category of antibiotics worldwide.
  • Antibiotics are the backbone of modern medicine and the Kundl plant is a testament to the resilience of European manufacturing.
  • The new development center in Holzkirchen will become a global hub for biosimilar expertise."

Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds

Retrieved on: 
Wednesday, November 8, 2023
FOR, J. P. Morgan, EBITDA, Person, Mizuho, NOT, OR, BNP Paribas, KID, Linklaters, BBB, Media release, S&P, AND, CHF, Security (finance), Bank, Novartis, BAA2, EUR, EEA

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

Key Points: 
  • NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN
    Inaugural Eurobonds priced earlier today; three tranches of EUR 700 million, EUR 700 million and EUR 600 million
    Basel, November 8, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announced the issuance of three highly successful inaugural Eurobonds, with total gross proceeds of EUR 2.0 billion.
  • Following a debut transaction in CHF last month, this issuance marks the entry of Sandoz into the EUR debt capital market.
  • Colin Bond, Sandoz CFO said: "These inaugural bonds represent a further milestone for Sandoz, establishing us firmly as a new issuer in the EUR bond market and creating a diversified and well-balanced financing profile from a currency and maturity perspective."
  • The proceeds, together with those from last month’s CHF issuance, will be used for the repayment of the EUR 2.4 billion bridge loan and for general corporate purposes.

Sandoz successfully issues CHF 750 million in inaugural bonds

Retrieved on: 
Thursday, October 26, 2023
EBITDA, Person, BNP Paribas, BBB, Media release, S&P, UBS, Failure, CHF, Security (finance), Bank, Novartis, BAA2

Two tranches of CHF 400 million and CHF 350 million with maturities of 3 and 8 years, carrying 2.125% and 2.600% fixed coupons, respectively

Key Points: 
  • Two tranches of CHF 400 million and CHF 350 million with maturities of 3 and 8 years, carrying 2.125% and 2.600% fixed coupons, respectively
    Basel, October 26, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announced the issuance of two highly successful inaugural CHF bonds with gross proceeds of CHF 750 million.
  • This debut transaction was driven by overwhelming investor demand and marks a solid entry for Sandoz as a borrower in debt capital markets.
  • The bonds carry 2.125% and 2.600% fixed coupons with tenors of 3 and 8 years, maturing on 17.11.2026 and 17.11.2031, respectively.
  • Sandoz continues to target a net debt to core EBITDA ratio of 1.7 to 2.0 times and to maintain its solid investment grade rating.

Kangankunde Rare Earths Concentrate Sale and Purchase Contract Signed with American Trading House

Retrieved on: 
Tuesday, September 26, 2023
Sale, REE, CT, MT, Metal, Marketing, LIN, Procurement, Risk management, ASX, Government, Monazite, Thorium, Federal government of the United States, Mining, International Atomic Energy Agency, Project, Media release, Commercial, Environment, Memory, Rare-earth element, Iron ore, Construction, Real estate, Sales, Uranium, Lindian County

The Contract provides for the supply and sale of 45,000 tonnes of rare earths concentrate from the Stage 1 development of the Kangankunde Rare Earth Project in Malawi.

Key Points: 
  • The Contract provides for the supply and sale of 45,000 tonnes of rare earths concentrate from the Stage 1 development of the Kangankunde Rare Earth Project in Malawi.
  • Gerald Metals SARL is part of the Gerald Group, the world's largest independent, employee-owned metal trading house, and one of the world's leading global commodity trading companies.
  • "This maiden Sale and Purchase Contract for rare earths concentrate provides one of the key enablers to advance Lindian to producer status by end-2024.
  • A summary of the mineral resource estimate for the Kangankunde Rare Earths Project is shown in the table below.

ACROMETA Signs Sales & Purchase Agreement for Additional 40% of Life Science Incubator

Retrieved on: 
Friday, March 31, 2023
Agreement, Vendor, Letter of intent, R & D, Biotechnology, Group purchasing organization, Research, Acquisition, LSI, Media release, Growth, Neurology, SME, Health insurance, Fine chemical, Pharmaceutical industry

Upon completion of the purchase, the Group will control 70% of LSI, up from the current 30%.

Key Points: 
  • Upon completion of the purchase, the Group will control 70% of LSI, up from the current 30%.
  • The Agreement updates and follows from the Letter of Intent ("LOI") announced to SGXNet on 20 February 2023 for the proposed acquisition of an additional 40% stake in LSI.
  • Mr Levin Lee Keng Weng, ACROMETA Chairman, said, "Brisbane is a booming hub for the Life Sciences sector in Australia.
  • The proposed additional co-working laboratory space in Singapore is to cater for expected growth in demand.

ACROMETA Acquires Controlling Stake in Co-Working Lab Space Company Life Science Incubator (LSI)

Retrieved on: 
Monday, February 20, 2023
DNA, Laboratory, German Centre for Rail Traffic Research, LSI, Media release, Medtech, Engineering, Research, SME, LOI, Health care, Partnership, Growth, Confidentiality, Dream, SGX, R, Airline, Fine chemical, Renewable energy, Biotechnology, Biopharma LLC

LSI currently operates a 6,500 sq feet co-working laboratory space at The German Centre in Singapore serving SMEs and start-ups.

Key Points: 
  • LSI currently operates a 6,500 sq feet co-working laboratory space at The German Centre in Singapore serving SMEs and start-ups.
  • Launched in September 2021, LSI at German Centre garners very healthy occupancy rates within a year of operations.
  • The additional stake will add another dimension of growth to the Group's business as it becomes not only a builder of laboratories but also an operator of co-working laboratory space.
  • "This potentially carves out a new promising mainstream business for us as controlled environment specialist", says ACROMETA Executive Chairman, Mr Levin Lee Keng Weng.

James Hardie Industries Announces Appointment of New Non-Executive Director

Retrieved on: 
Friday, December 2, 2022
Other Construction & Property, Construction & Property, Other Manufacturing, Manufacturing, Cloud, NYSE, University, Toro (company), Information technology, CFO, 2nd Floor (Nina song), MBA, Harcourt Street, Eaton, James Hardie Industries, Media release, ASX, Honeywell, Environment, Certification, JHX, Management

James Hardie Industries plc (ASX: JHX; NYSE: JHX), the worlds #1 producer and marketer of high-performance fiber cement and fiber gypsum building solutions, is pleased to announce the appointment of Renee J. Peterson as an independent non-executive director of James Hardie effective 30 November 2022.

Key Points: 
  • James Hardie Industries plc (ASX: JHX; NYSE: JHX), the worlds #1 producer and marketer of high-performance fiber cement and fiber gypsum building solutions, is pleased to announce the appointment of Renee J. Peterson as an independent non-executive director of James Hardie effective 30 November 2022.
  • Commenting on the appointment, Anne Lloyd, Chairperson of James Hardie, said, I am delighted Renee has agreed to join our Board.
  • James Hardie assumes no obligation to update or correct the information contained in this Media Release except as required by law.
  • James Hardie Industries plc is a limited liability company incorporated in Ireland with its registered office at Europa House, 2nd Floor, Harcourt Centre, Harcourt Street, Dublin 2, D02 WR20, Ireland
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221201006083/en/

James Hardie Industries Announces Chairperson Appointment

Retrieved on: 
Thursday, November 3, 2022
Manufacturing, Other Manufacturing, Other Construction & Property, Architecture, Construction & Property, James Hardie Industries, 2nd Floor (Nina song), NYSE, ASX, Harcourt Street, Growth, JHX, Board, Chairperson, Media release, Management

James Hardie Industries plc (ASX: JHX; NYSE: JHX), the worlds #1 producer and marketer of high-performance fiber cement and fiber gypsum building solutions, today announces that Anne Lloyd, previously announced as the Chairperson successor on 10 August 2022, has been officially appointed as the Chairperson, effective 3 November 2022 Dublin time.

Key Points: 
  • James Hardie Industries plc (ASX: JHX; NYSE: JHX), the worlds #1 producer and marketer of high-performance fiber cement and fiber gypsum building solutions, today announces that Anne Lloyd, previously announced as the Chairperson successor on 10 August 2022, has been officially appointed as the Chairperson, effective 3 November 2022 Dublin time.
  • I would like to congratulate Anne Lloyd on her appointment as Chairperson and I wish her the very best.
  • Commenting on her formal appointment, Ms. Lloyd said, I am grateful and thrilled to have the opportunity to take on this critical role as Chairperson of the James Hardie Board of Directors.
  • James Hardie Industries plc is a limited liability company incorporated in Ireland with its registered office at Europa House, 2nd Floor, Harcourt Centre, Harcourt Street, Dublin 2, D02 WR20, Ireland
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221103006405/en/

James Hardie Industries Announces Management Appointments

Retrieved on: 
Thursday, November 3, 2022
Other Construction & Property, Construction & Property, Other Manufacturing, Manufacturing, James Hardie Industries, Business administration, Company, VP, London Business School, Growth, Air Liquide, ESG, Industry, Transformation, Heinrich Heine University Düsseldorf, NYSE, MIT Sloan School of Management, ASX, 2nd Floor (Nina song), CEO, Harcourt Street, Harvard Business School, Executive education, JHX, Media release, Management, Tarkett

James Hardie Industries plc (ASX: JHX; NYSE: JHX), the worlds #1 producer and marketer of high-performance fiber cement and fiber gypsum building solutions, today announces the appointment of Christian Claus as President Europe.

Key Points: 
  • James Hardie Industries plc (ASX: JHX; NYSE: JHX), the worlds #1 producer and marketer of high-performance fiber cement and fiber gypsum building solutions, today announces the appointment of Christian Claus as President Europe.
  • Mr. Claus joins James Hardie as President Europe from a successful leadership career in large global industrial B2B and B2B2C businesses.
  • James Hardie assumes no obligation to update or correct the information contained in this Media Release except as required by law.
  • James Hardie Industries plc is a limited liability company incorporated in Ireland with its registered office at Europa House, 2nd Floor, Harcourt Centre, Harcourt Street, Dublin 2, D02 WR20, Ireland
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221103006359/en/

MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing

Retrieved on: 
Friday, September 9, 2022
Research, Technology, Medical Devices, FDA, Software, Biotechnology, General Health, Health, Science, Other Science, Private placement, Price, Regulation of tobacco by the U.S. Food and Drug Administration, Therapeutic Goods Administration, Closed-end fund, TSX Venture Exchange, Medarex, Physician, Food, Union, Health Canada, TSX, Moles, Funding, Company, Stock exchange, Press release, Global Health Corps, Private, Light, Dermatology, Media release, Security (finance)

No Cash Commissions or Agents Warrants were paid or issued in relation to those seven Convertible Notes.

Key Points: 
  • No Cash Commissions or Agents Warrants were paid or issued in relation to those seven Convertible Notes.
  • Securities issued on are subject to a four month restriction from trading in accordance with relevant regulatory and stock exchange policies.
  • The Company also has further subscriptions in hand for $500,000 which are in process of being funded, and additional subscriptions are anticipated.
  • SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility.